Key result
Direct oral anticoagulants showed similar rates of stroke (0% vs 2%, P=0.55) and clinically significant bleeding (0% vs 10%, P=0.13) compared to vitamin K antagonists for left ventricular thrombus.
Why the study?
LV thrombus is increasingly detected, but the comparative efficacy and safety of DOACs versus VKAs for this condition required evaluation.
Does DOAC therapy prevent thromboembolism and reduce bleeding compared to VKA in patients with left ventricular thrombus?
Population
84 patients diagnosed with and managed for LV thrombus
Comparison
DOAC vs VKA
Design
Retrospective observational cohort study
Follow-up
Average 3.0 ± 1.4 years
Authors
Loading...
Supports DOAC use as VKA alternative for LV thrombus; leaves open confirmation of noninferiority in randomized trials.
Cohort (n=84)
Does DOAC therapy prevent thromboembolism and reduce bleeding compared to VKA in patients with left ventricular thrombus?
Absolute Event Rate: 0% vs 2%
p-value: p=0.55
DOACs appear to be as effective and safe as VKAs for the management of left ventricular thrombus, offering a potentially more convenient off-label alternative.
Iqbal et al. (2020) conducted a cohort in Left ventricular thrombus (n=84). Direct oral anticoagulants (DOAC) vs. Vitamin K antagonist (VKA) was evaluated on stroke (p=0.55). Direct oral anticoagulants showed similar rates of stroke (0% vs 2%, P=0.55) and clinically significant bleeding (0% vs 10%, P=0.13) compared to vitamin K antagonists for left ventricular thrombus.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: